IL1B and COVID-19: Exoproteome-targeting autoantibodies, which can perturb cell signaling and targeted killing of specific cell populations via Fc receptors and complement as well as suppress IL-1β, GM-CSF, and IL-21, are prominent in acute COVID-19 regardless of clinical stage (129).